AstraZeneca plans to enhance its global supply of antibody drug conjugates (ADCs) portfolio by building a $1.5bn (USD) manufacturing facility in Singapore.
It will be the biopharmaceutical company’s first-ever facility to cover the full manufacturing process for ADCs.
AstraZeneca aims to begin design and construction of the manufacturing facility by the end of 2024, with targeted operational readiness from 2029.
ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.
The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale.
This facility will be designed to emit zero carbon from its first day of operations
Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance.
Pascal Soriot, CEO of AstraZeneca, said: “AstraZeneca has built an industry-leading portfolio of cancer medicines including antibody-drug conjugates which have shown enormous potential to replace traditional chemotherapy for patients across many settings. Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for AstraZeneca to locate our $1.5 billion ADC manufacturing facility in the country.”
AstraZeneca has a broad portfolio of in-house ADCs including six wholly owned ADCs in the clinic and many more in preclinical development.
ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells
As part of AstraZeneca's commitment to driving sustainability in healthcare, the company will work with Singapore's government and other partners on green solutions for the ADC facility. This facility will be designed to emit zero carbon from its first day of operations.
Png Cheong Boon, Chairman, EDB said: "We welcome AstraZeneca's decision to establish a manufacturing presence in Singapore for the first time. It will also be a first for AstraZeneca – an end-to-end manufacturing facility for novel antibody drug conjugates that enables precision therapy for cancer.”
“This greenfield investment is a strong show of confidence in Singapore's biopharmaceutical manufacturing capabilities and talent, strengthens our ecosystem in supporting the development and manufacturing of precision medicines, and creates meaningful jobs and economic opportunities for Singapore. We look forward to a successful partnership with AstraZeneca,” Boon concluded.
